Acta Med. 2002, 45: 155-160
https://doi.org/10.14712/18059694.2019.73
Diagnostic Value of C-Reactive Protein in Patients with Angiographically Documented Coronary Heart Disease
References
1. Am Heart J 1999; 2:346–51.
< I, Danchin N, Ilardo C, Aimone-Gastin I, Le Faou A. C-reactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes. https://doi.org/10.1053/hj.1999.v137.92052>
2. Ann NY Acad Sci 1982; 389:49–75.
< ML, de Beer FC, Feinstein A et al. Pylogenetic aspects of C-reactive protein and related proteins. https://doi.org/10.1111/j.1749-6632.1982.tb22125.x>
3. Arterioscler Thromb Vasc Biol 1999; 19:2348–54.
< S, Torzewski M, Klouche M, Hemmes M. Complement activation and atherogenesis. Binding of CRP to degraded, nonoxidised LDL enhances complement activation. https://doi.org/10.1161/01.ATV.19.10.2348>
4. Blood 1993; 82:513–20.
JC, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor.
5. Jama 1998; 279:1477–88.
< J, Collins R, Applebly P, Peto R. Association of fibrinogen , C-reactive protein, albumin or leukocyte count with coronary heart disease. https://doi.org/10.1001/jama.279.18.1477>
6. J Exp Med 1982; 156:230–42.
< FC, Soutar AK, Baltz ML, Trayner I, Feinstein A, Pepys MB. Low density and very low density lipoproteins are selectively bound by aggregated C-reactive protein. https://doi.org/10.1084/jem.156.1.230>
<PubMed>
7. Circulation 1999; 100(19):1958–63.
< ER, Boissonnet CP, Pizarro R et al. Independent prognostic value of elevated C-reactive protein in unstable angina. https://doi.org/10.1161/01.CIR.100.19.1958>
8. Am J Cardiol 2001; 88(2):112–7.
< AR, Pankow JS, Tracy RP et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease. https://doi.org/10.1016/S0002-9149(01)01603-4>
9. Clin Chem 1972; 18(6):499–502.
WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
10. J Exp Med 1999; 190(12):1733–40.
< M, Herbert J, Hutchinson WL et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. https://doi.org/10.1084/jem.190.12.1733>
<PubMed>
11. Immunol Today 1997; 18:111–5.
< CE, Wolbink GJ, Schalkwijk C, Speijer H, Hermens WT, van den Bosch H. A role for secretory phospholipase A2 and C-reactive proteins in the removal of injured cells. https://doi.org/10.1016/S0167-5699(97)01002-5>
12. Clin Biochem 2001; 33:309–15.
< M, Jaradi E, Sadeghi B, Hajilasi M, Ghanbili J. Evaluation of C-reactive protein asensitive marker of inflammation as risk factor for stable coronary artery disease. https://doi.org/10.1016/S0009-9120(01)00227-2>
13. Radiology 1967; 89:815–24.
< MP. Selective coronary arteriography. I. A percutaneous transfemoral technique. https://doi.org/10.1148/89.5.815>
14. Am J Epidemiol 1996; 144:537–47.
LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study.
15. Arterioscler Thromb Vasc Biol 2000; 20(4):901–6.
< LH, Tracy RP. The role of inflammation in cardiovascular disease. https://doi.org/10.1161/01.ATV.20.4.901>
16. Clin Chem 1997; 43(1):52–8.
EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications.
17. Am J Cardiol 2001; 88(6):601–7.
< A, Sansoy V, Yildirim B, Keles I, Uysal O and Hergenc G. C-reactive protein and coronary heart disease in western Turkey. https://doi.org/10.1016/S0002-9149(01)01799-4>
18. Circulation 2000; 101:235–8.
< V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. https://doi.org/10.1161/01.CIR.101.3.235>
19. Adv Immunol 1983; 34:141–212.
< MB, The acute phase response with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. https://doi.org/10.1016/S0065-2776(08)60379-X>
20. Nature 1978; 273:168–70.
< MB, Dash AC, Fletcher TC, Richardson N, Munn EA, Feinstein A. Analogs in other mammals and in fish of human plasma proteins C- reactive protein and amyloid P component. https://doi.org/10.1038/273168a0>
21. N Engl J Med 2000; 342(12):836–43.
< PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. https://doi.org/10.1056/NEJM200003233421202>
22. Circulation 1998; 97:425–8.
< PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. https://doi.org/10.1161/01.CIR.97.5.425>
23. Clin Chem. 1999; 45(11): 1967–73.
N, Joubran R, Yu H, Asmi M, Jouma M. Inflammatory markers in men with angiographically documented coronary heart disease.
24. Clin Chem 1999; 45(12):2136–41.
N, Tracy RP, Ridker PM. Clinical efficacy of an automated high sensitivity C-reactive protein assay.
25. Circulation 2000; 101(15):1758–65.
< PK. Circulating markers of inflammation for vascular risk prediction: Are they ready for prime time. https://doi.org/10.1161/01.CIR.101.15.1758>
26. Structure 1999; 7:169–77.
< D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. https://doi.org/10.1016/S0969-2126(99)80023-9>
27. Clin Chem Lab Med 1999; 37(5):495–503.
< J, Biasucci L, Rifai N. Inflammation, the acute phase response and atherosclerosis. https://doi.org/10.1515/CCLM.1999.080>